Led by University of Oxford researchers, the Platform Randomised trial of Interventions against Covid-19 In older peoPLE (PRINCIPLE) trial is investigating treatments for early-stage Covid-19 that can reduce overall recovery time and the burden of symptoms, and prevent the need for hospital admission.
Colchicine is an inexpensive anti-inflammatory drug widely used in the UK for many years as a treatment for acute gout. In Canada’s ColCorona trial, the drug has recently shown promise in reducing hospital admissions in patients with Covid-19, yet little is known about its effectiveness in reducing recovery time or the burden of the illness.
Previously, only those with Covid-19 aged 50 or over and at most risk of complications from the illness were eligible to join the PRINCIPLE trial. For the colchicine arm, the trial now includes participants either aged 18-64 with shortness of breath from the illness or certain underlying health conditions that put them at risk of severe illness, or those aged over 65. Participants are only eligible to join the trial during the first 14 days of Covid-19 illness.
Since launching in March 2020, PRINCIPLE has so far recruited more than 4400 volunteers from across the UK, making it the largest trial of Covid-19 treatments to take place in community settings.
With the vaccine programme continuing at pace in vulnerable adults, and the remaining urgent need for evidence-based treatments for recovery at home, expanding parts of the trial to people aged under 50 will provide new insights into whether treatments can help those at greater risk of severe Covid-19 illness.
A vast network of community health and care organisations across the UK’s four nations now support patient recruitment into PRINCIPLE, and the Oxford team are today renewing their call for eligible adults with early Covid-19 symptoms to consider joining the trial.
PRINCIPLE trial co-lead, Professor Chris Butler, a general practitioner and Professor of Primary Care at the University Oxford’s Nuffield Department of Primary Care Health Sciences, said:
‘We are asking for eligible volunteers aged over 18 from all across the country to join the PRINCIPLE trial when they first experience Covid-19 symptoms, and help in the search for potential treatments. With Covid-19 still circulating in the community, and little known about the effect of new viral variants on younger adults, it is vital that we seize this window of opportunity to generate high-quality evidence to determine which treatments work, and which don’t.
‘Even with successful vaccines and other preventable measures in place, the availability of treatments with a solid evidence-base has a critical role to play in ending this pandemic, yet there are still very few options for treating Covid-19 before it becomes a severe illness.’
Minister for Innovation Lord Bethell said:
‘The UK continues to be a leading force in finding and rolling out safe and effective treatments for Covid-19, with life-saving treatments dexamethasone and tocilizumab identified by our research. The government-funded PRINCIPLE trial presents an exciting opportunity to find treatments outside of hospital, stopping people’s symptoms from worsening at an earlier stage of the disease.
‘The expansion of the trial, with a new treatment arm that is open to a wider patient cohort, is a promising development - I encourage as many eligible people as possible over the age of 18 to sign up to the trial and play a vital role in finding more treatments for this terrible virus.’
Following a screening questionnaire to confirm eligibility, participants will be randomly assigned a study drug or the usual standard-of-care NHS treatment. Those assigned to colchicine will receive a 14-day course of 500 micrograms (mcg) colchicine tablets, will be followed-up for 28 days and will be compared with participants who have been assigned to receive only the usual standard-of-care.
Those excluded from the colchicine study include women who are pregnant or breastfeeding, people taking certain medications, or those with inflammatory bowel disease.
People with coronavirus symptoms, or a positive test result, can join the trial easily online, over the telephone or via their GP practice from anywhere in the UK, without needing face-to-face visits with the trial team in Oxford.
The decision to widen the trial’s inclusion criteria and include colchicine was made by the University of Oxford researchers and the trial steering committee in conjunction with Chief Medical Officer for England, following a recommendation by the UK COVID-19 Therapeutics Advisory Panel.
The PRINCIPLE trial has so far determined that the antibiotics azithromycin and doxycycline are not effective treatments during the early stages of Covid-19. The trial continues to investigate budesonide, an inhaled corticosteroid, in people aged over 50.
PRINCIPLE is funded by a grant to the University of Oxford from UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research as part of the UK Government’s rapid research response fund.
To find out more about how to join the study, visit www.principletrial.org or call 0800 138 0880.